Impact of androgen deprivation on physical well‐being in patients with prostate cancer

As androgen deprivation therapy (ADT) becomes a standard of treatment for men with recurrent or metastatic prostate cancer, evaluation of adverse effects associated with this treatment is needed. In this study, the authors evaluated the effect of ADT administered as monotherapy and in combination with local treatment on physical well‐being in a longitudinal sample of men with prostate cancer.

[1]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[2]  Juliessa M Pavon,et al.  Physical Performance and Subsequent Disability and Survival in Older Adults with Malignancy: Results from the Health, Aging and Body Composition Study , 2010, Journal of the American Geriatrics Society.

[3]  P. Carroll,et al.  Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE™ (cancer of the prostate strategic urologic research endeavor) database , 2009, Quality of Life Research.

[4]  P. Warde,et al.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  R. Munver,et al.  Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months , 2009, Supportive Care in Cancer.

[7]  M. Cooperberg,et al.  Health related quality of life in patients treated with multimodal therapy for prostate cancer. , 2008, The Journal of urology.

[8]  S. Mohile,et al.  Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. , 2008, Urology.

[9]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[10]  Thomas O. Blank,et al.  A gerontologic perspective on cancer and aging , 2008, Cancer.

[11]  S. Perera,et al.  Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. , 2008, Urology.

[12]  J. Wei.  Long-Term Quality of Life Among Dutch Prostate Cancer Survivors: Results of a Population-Based Study , 2007 .

[13]  S. Mohile,et al.  Does androgen‐deprivation therapy accelerate the development of frailty in older men with prostate cancer? , 2007, Cancer.

[14]  A. D'Amico,et al.  Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.

[15]  S. Sereika,et al.  Quality of Life in Prostate Cancer Patients Taking Androgen Deprivation Therapy , 2006, Journal of the American Geriatrics Society.

[16]  J. Nelson,et al.  Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  Kirsten L. Greene,et al.  Who is the average patient presenting with prostate cancer? , 2005, Urology.

[18]  P. Walsh.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The Journal of urology.

[19]  J. Goodwin,et al.  Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.

[20]  M. Cooperberg,et al.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Fried.  Establishing Benchmarks for Quality Care for an Aging Population: Caring for Vulnerable Older Adults , 2003, Annals of Internal Medicine.

[22]  M. Cooperberg,et al.  National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.

[23]  J. Stanford,et al.  General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Renshaw,et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.

[25]  F. J. Fowler,et al.  The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma , 2002, Cancer.

[26]  D. Lubeck,et al.  The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. , 2001, Urology.

[27]  D. Lubeck,et al.  The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. , 2001, Journal of clinical epidemiology.

[28]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[29]  J E Ware,et al.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. , 1998, Journal of clinical epidemiology.

[30]  M. Litwin,et al.  Health-related quality of life in men with prostate cancer , 1998, Prostate Cancer and Prostatic Diseases.

[31]  D. Lubeck,et al.  The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. , 1996, Urology.

[32]  C. Sherbourne,et al.  The RAND 36-Item Health Survey 1.0. , 1993, Health economics.

[33]  L. Breslow,et al.  A quantitative approach to the World Health Organization definition of health: physical, mental and social well-being. , 1972, International journal of epidemiology.

[34]  J. Eastham,et al.  Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer , 2009, Prostate Cancer and Prostatic Diseases.

[35]  H. Sandler,et al.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Litwin,et al.  Predictors of fatigue after treatment for prostate cancer. , 2005, Urology.

[37]  M. Cooperberg,et al.  Patterns of practice in the United States: Insights from CaPSURE on prostate cancer management , 2004, Current urology reports.

[38]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.